(E)-3-(dimethylamino)-1-(2,4-dimethylthiazol-5-yl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-(dimethylamino)-1-(2,4-dimethylthiazol-5-yl)prop-2-en-1-one
• 英文别名: 3-(N,N-dimethylamino)-1-(2,4-dimethyl-thiazol-5-yl)propenone；3-dimethylamino-1-(2,4-dimethylthiazol-5-yl)propenone；3-dimethylamino-1-(2,4-dimethyl-thiazol-5-yl)-propenone；3-(Dimethylamino)-1-(2,4-dimethyl-1,3-thiazol-5-yl)prop-2-en-1-one；(E)-3-(dimethylamino)-1-(2,4-dimethyl-1,3-thiazol-5-yl)prop-2-en-1-one
• 化学式: C₁₀H₁₄N₂OS
• 分子量: 210.3
• InChiKey: NCHMJHFUGUCVFT-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-(dimethylamino)-1-(2,4-dimethylthiazol-5-yl)prop-2-en-1-one 在 sodium hydroxide 、 铁粉 、 溶剂黄146 作用下， 以 乙醇 、 乙二醇甲醚 为溶剂， 反应 22.5h， 生成 N-{4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl}-benzene-1,3-diamine
  参考文献：
  名称：

  2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors:  Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

  摘要：

  Following the identification through virtual screening of 4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analogue program was initiated. The first aims were to optimize potency and to evaluate the cellular mode of action of lead candidate molecules. Here the synthetic chemistry, the structure-guided design approach, and the structure-activity relationships (SARs) that led to the discovery of 2-anilino-4-(thiazol-5-yl)pyrimidine ATP-antagonistic CDK2 inhibitors, many with very low nM K(i)s against CDK2, are reported. Furthermore, X-ray crystal structures of four representative analogues from our chemical series in complex with CDK2 are presented, and these structures are used to rationalize the observed biochemical SARs. Finally results are reported that show, using the most potent CDK2 inhibitor compound from the current series, that the observed antiproliferative and proapoptotic effects are consistent with cellular CDK2 and CDK9 inhibition.

  DOI：

  10.1021/jm0309957
• 作为产物：
  描述：

  2,4-二甲基-5-乙酰基噻唑 以 N,N-二甲基甲酰胺二甲基缩醛 为溶剂， 以79%的产率得到(E)-3-(dimethylamino)-1-(2,4-dimethylthiazol-5-yl)prop-2-en-1-one
  参考文献：
  名称：

  Anti-cancer compounds

  摘要：

  本发明涉及2-取代的4-杂环芳基嘧啶、其制备、含有它们的药物组合物以及它们作为细胞周期依赖性激酶（CDKs）抑制剂的用途，因此可用于治疗癌症、白血病、牛皮癣等增生性疾病。

  公开号：

  US20020019404A1

文献信息

• Efficient Organocatalytic Dual Activation Strategy for Preparing the Versatile Synthons (2E)-1-(Het)Aryl/styryl-3-(dimethylamino)prop-2-en-1-ones and α-(E)-[(Dimethylamino)methylene]cycloalkanones
  作者：Asit Chakraborti、Sachin Bindal、Dinesh Kumar、Damodara Kommi、Sonam Bhatiya

  DOI：10.1055/s-0030-1260048

  日期：2011.6

  A novel organocatalytic dual activation strategy is reported for an efficient synthesis of the versatile synthons (2E)-1-aryl/heteroaryl/styryl-3-(dimethylamino)prop-2-en-1-ones and α-(E)-[(dimethylamino)methylene]cycloalkanones. 2-Guanidinoacetic acid (10 mol%) serves as an ambifunctional organocatalyst for the reaction of various aryl/heteroaryl/styryl methyl ketones and cyclic ketones having an

  报道了一种新颖的有机催化双重活化策略，用于有效合成通用的合成子（2 E）-1-芳基/杂芳基/苯乙烯基-3-（二甲氨基）丙-2-烯-1-酮和α-（E）- [（二甲基氨基）亚甲基]环烷酮。2-胍基乙酸（10 mol％）用作双官能团有机催化剂，可在100°C下将各种具有α-亚甲基部分的芳基/杂芳基/苯乙烯基甲基酮和环状酮与N，N-二甲基甲酰胺二甲基乙缩醛反应成1-在无溶剂的条件下3小时，以72-95％的产率得到相应的（2 E）-3-（二甲基氨基）丙-2-烯-1-酮。 2-胍基乙酸-有机催化剂-双活化-3-（二甲基氨基）丙烯酮-芳基甲基酮-N，N-二甲基甲酰胺二甲基乙缩醛
• <scp>L</scp>-Proline-Catalyzed Activation of Methyl Ketones or Active Methylene Compounds and DMF-DMA for Syntheses of (2<i>E</i>)-3-Dimethylamino-2- propen-1-ones
  作者：Dinesh Kumar、Damodara N. Kommi、Pradeep Chopra、Md Imam Ansari、Asit K. Chakraborti

  DOI：10.1002/ejoc.201200778

  日期：2012.11

  place in the reaction of methyl ketones or active methylene compounds with DMF-DMA (N,N-dimethylformamide dimethyl acetal). L-Proline serves as an efficient organocatalyst in the covalent and noncovalent synchronous mode for the ambiphilic activation of various aryl, heteroaryl, and styryl methyl ketones, cyclic ketones, and 1,3-diketones with DMF-DMA to achieve the convenient syntheses of the versatile

  据报道，在甲基酮或活性亚甲基化合物与 DMF-DMA（N，N-二甲基甲酰胺二甲基乙缩醛）反应中发生亲核和亲电双重活化的级联有机催化。L-脯氨酸在共价和非共价同步模式下作为一种有效的有机催化剂，用于各种芳基、杂芳基和苯乙烯基甲基酮、环酮和 1,3-二酮与 DMF-DMA 的两亲性活化，以实现方便的合成多功能合成子 (2E)-1-芳基/杂芳基/苯乙烯基-3-(二甲氨基)-2-丙烯-1-酮、(E)-α-[(二甲氨基)甲叉]环烷酮和(E)-2-(在无溶剂条件下以高产率制备二甲氨基)甲亚基-1,3-二酮。
• [EN] N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS<br/>[FR] DÉRIVÉS DE N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL) PYRIMIDIN-2-AMINE UTILISÉS COMME COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV SOUTH AUSTRALIA

  公开号：WO2017020065A1

  公开（公告）日：2017-02-09

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:

  这是一类新型的蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病况，特别是那些表现为CDK4、CDK6和/或cyclin D过度表达的疾病，包括肺癌、乳腺癌、脑部、中枢神经系统、结肠直肠癌和白血病等。这些抑制剂具有一般式I的结构。
• Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
  申请人：Siga Technologies, Inc.

  公开号：US20130129677A1

  公开（公告）日：2013-05-23

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

  本发明揭示了使用某些噻唑吡啶衍生物化合物以治疗病毒感染的方法和制药组合物，通过以治疗有效剂量给药。同时还揭示了使用这些化合物和制药组合物的方法。具体地，揭示了治疗由黄热病毒、日本脑炎病毒、西尼罗河病毒、登革热病毒和蜱媒脑炎病毒等引起的病毒感染的方法。
• N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
  申请人：UNIVERSITY OF SOUTH AUSTRALIA

  公开号：US10479785B2

  公开（公告）日：2019-11-19

  A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:

  一类新型蛋白激酶抑制剂，可用于治疗细胞增殖性疾病和病症，特别是以 CDK4、CDK6 和/或细胞周期蛋白 D 过度表达为特征的疾病和病症，包括某些肺癌、乳腺癌、脑癌、中枢神经系统癌、结直肠癌和白血病。这些抑制剂具有一般结构 I：